NextCure Announces Merger Agreement to Combine with Avere Therapeutics

What Happened

• On July 14, 2026 NextCure, Inc. filed an 8-K announcing a definitive Agreement and Plan of Merger to combine with Avere Therapeutics. The transaction contemplates a two-step merger under which Avere will become a wholly owned subsidiary of NextCure and then be merged into a NextCure subsidiary, with the combined company to be led by Avere’s CEO. The deal includes a concurrent private placement (PIPE) for approximately $320 million and is expected to close in the third quarter of 2026, subject to stockholder and regulatory approvals.

Key Details

• Financing: Institutional and accredited investors agreed to buy PIPE securities for ~ $320 million in a private placement; the Merger closing requires proceeds of at least $150 million (and related closing conditions).
• Ownership: Pro forma (after the PIPE and based on expected issuances), pre‑Merger Avere stockholders would own ~98.11% of the combined company and pre‑Merger NextCure stockholders ~1.89% (subject to adjustments).
• NextCure actions: NextCure will seek stockholder approval to issue shares in the Merger, amend its charter (including possible reverse split, increasing authorized shares, redomicile, and a name change to “Avere Therapeutics, Inc.”), accelerate vesting of NextCure equity awards prior to closing, and enter a Contingent Value Rights (CVR) agreement for pre‑Merger NextCure holders (CVRs pay 90% of gross proceeds from certain legacy-asset dispositions if any).
• Workforce and programs: The board approved a restructuring expected to begin July 2026 that will reduce a substantial majority of NextCure’s workforce in Q3 2026, with estimated one‑time cash charges of ~$1.9 million (primarily severance and related costs). NextCure also announced it will stop expanding SIM0505 clinical sites into Europe/Canada and cease new U.S. enrollments, and has opted out of continued cost‑sharing for LNCB74 with collaborator LigaChem.

Why It Matters

• For investors, the filing shows a fundamental change in NextCure’s business: a near‑complete ownership flip to Avere holders, a major new financing, board and management changes, and corporate restructuring actions that include potential redomicile and a name change.
• The PIPE and financing conditions are material to whether the Merger closes; the deal also creates potential dilution and governance shifts (Avere‑designated board and management).
• The workforce reduction and program changes (SIM0505 and LNCB74) affect NextCure’s near‑term operating costs and clinical portfolio: management expects ~$1.9M in one‑time charges in Q3 2026 and has signaled a strategy to seek partners or monetization for certain assets (including via the CVR structure), but there is no assurance of proceeds.

Keywords: merger, acquisition, PIPE financing, workforce reduction, clinical program, CVR, reverse split, NextCure, Avere.